JAK inhibitor withdrawal causes a transient pro-inflammatory cascade: A potential mechanism for major adverse cardiac events [0.03%]
JAK抑制剂撤药导致的短暂促炎症级联反应：潜在的心脏不良事件机制
Ilya Gurevic,Loic Meudec,Xavier Mariette et al.
Ilya Gurevic et al.
Objective: Our objective was to define the effect of JAK inhibitor (JAKinib) withdrawal on JAK/STAT biochemical response in the context of systemic rheumatic diseases. ...
Erica B Lee,Kelly M Cordoro
Erica B Lee
Purpose of review: JAK inhibitors have emerged as a promising new therapy for inflammatory skin disease, including in pediatric populations. However, due to their boxed warnings and lack of long-term safety and efficacy d...
Tanaz A Kermani,Kenneth J Warrington
Tanaz A Kermani
Giant cell arteritis is a large-vessel vasculitis affecting the aorta and its branches. While treatment with glucocorticoids is efficacious in the initial management, patients experience relapses and adverse effects. The results of a clinic...
Changes in NK Cells and Exhausted Th Cell Phenotype in RA Patients Treated with Janus Kinase Inhibitors: Implications for Adverse Effects [0.03%]
JAK抑制剂治疗的类风湿关节炎患者的NK细胞和耗竭性T细胞表型变化：不良反应的意义
Juan José Fernández-Cabero,Carmen Lasa-Teja,David San Segundo et al.
Juan José Fernández-Cabero et al.
Recent concerns regarding the safety of Janus kinase inhibitors (JAKis) have prompted investigation into their impact on immune cell subsets in rheumatoid arthritis (RA) patients. This study aims to analyse alterations in immune cell popula...
Francesca Bernardi,Ilaria Faggiani,Tommaso Lorenzo Parigi et al.
Francesca Bernardi et al.
Janus kinase inhibitors, including tofacitinib, filgotinib, and upadacitinib, have emerged as effective therapeutic options for the management of inflammatory bowel diseases (IBDs). By targeting the JAK-STAT signaling pathway, these agents ...
Janus kinase (JAK) inhibitor-induced acne in inflammatory bowel disease - an international, multicenter, retrospective cohort study [0.03%]
janus激酶(JAK)抑制剂诱导的炎症性肠病患者痤疮：一项国际多中心回顾队列研究
Sailish Honap,Maria José Temido,Eathar Shakweh et al.
Sailish Honap et al.
Background and aims: JAK inhibitor-associated acne is a common but poorly understood adverse event. This study aimed to investigate the epidemiology, clinical characteristics, and treatment outcomes of this condition in p...
Epigenomic landscapes define differential Janus kinases inhibitor sensitivity in IFN-γ-primed human macrophages [0.03%]
表观基因组景观定义了I型干扰素预处理的人类巨噬细胞中JAK抑制剂的敏感性差异
Geunho Kwon,Yebin Park,Keunsoo Kang et al.
Geunho Kwon et al.
Janus kinases (JAK) mediate signaling pathways of multiple cytokines, including interferon-γ (IFN-γ), which plays a pivotal role in rheumatoid arthritis (RA) pathogenesis. Although JAK inhibitors (JAKi) have demonstrated efficacy for RA, ...
NK cell cytotoxicity is markedly reduced in younger patients with rheumatoid arthritis treated with JAK inhibitors [0.03%]
接受JAK抑制剂治疗的年轻类风湿关节炎患者的自然杀伤细胞细胞毒作用明显降低
Takahiko Akagi,Yasumitsu Nishimura,Shunichi Fujita et al.
Takahiko Akagi et al.
Objectives: This study investigated the impact of Janus kinase inhibitors (JAKi) on natural killer (NK) cell activity and phenotype in patients with rheumatoid arthritis (RA). While JAKi are effective in achieving low dis...
Pilot Study of Low-Dose Splenic Irradiation and Transplantation in JAK Inhibitor-Refractory Myelofibrosis with Splenomegaly [0.03%]
脾放疗联合移植治疗JAK抑制剂难治性伴脾大的骨髓纤维化小规模临床研究
Kristin Rathje,Nico Gagelmann,Artur Schneider et al.
Kristin Rathje et al.
Background: Splenomegaly is a hallmark feature of myelofibrosis, driven by extramedullary hematopoiesis due to progressive bone marrow fibrosis. Enlarged spleens cause significant symptoms, impair quality of life, and com...
耗时 0.15446 秒，为您在
48252782
条记录里面共找到 1368 篇文章 [XML]